Sector News

Indian pharma’s struggle to tighten standards paves way for M&A deals

June 29, 2015
Life sciences
India’s smaller generic drugmakers, struggling to cope with a bruised reputation and tougher regulation in the United States, are under pressure to consider branching out to new, less-profitable markets or sell out to larger rivals.
 
Two years after its most high-profile regulatory setback to date in the United States – Ranbaxy’s (RANB.NS) $500 million U.S. fine for drug safety violations – India’s $15 billion a year generic drug industry is still rebuilding its image in its biggest market.
 
Many of its top firms are facing sanctions at some of their factories, as the U.S. Food and Drug Administration (FDA) tightens checks and its approvals process.
 
Combined with government-mandated price controls on drugs at home, that is piling pressure on smaller players.
 
“If they want to have a presence globally, they have to make investments. If they can’t, then they’ll have to focus on other markets or scale back their ambition outside of India, and that’s probably what will happen,” said Subhanu Saxena, CEO of Cipla (CIPL.NS), India’s fourth-largest drugmaker by revenue.
 
Ashok Anand, president of Hikal Ltd (HIKA.NS), a Mumbai-based drugmaker with a market value of $167 million, said some peers were putting themselves on the block.
 
“If they cannot deal with the stricter regulations, they might just prefer to sell out,” he said.
 
Pressure on U.S. sales has been felt across the Indian industry, with all drugmakers hit by delays in FDA approvals as the U.S. safety body overhauls its review process. Growth in U.S. revenue for drugmakers slowed to 14 percent in the year to March 2015, less than half what it was in the year to March 2012, according to brokerage Edelweiss.
 
But for larger players who want to plug gaps or, for the likes of Glenmark (GLEN.NS) and Aurobindo (ARBN.NS) who aim to grow in the United States, this pressure has lowered prices and could pave the way for attractive deals, bankers said.
 
“Now that some of the smaller companies are reeling under intensive regulatory scrutiny and want to cash out on their investments, valuations would be much more realistic,” said the head of India M&A at a large European bank in Mumbai.
 
SPENDING SPREE
 
Indian manufacturers say they have spent millions in high-end testing equipment, improved training and have hired larger teams in quality control since Ranbaxy was fined for manipulating clinical data.
 
Some consultants estimate spending on compliance has more than doubled to reach about 6 to 7 percent of sales for the larger companies.
 
But while the number of U.S. export bans issued to Indian companies fell to eight in 2014 from 21 in 2013, according to FDA data, the agency continues to find manufacturing violations at the plants of some of the biggest drugmakers in the country, an indication of the pervasiveness of the problem.
 
Sun Pharmaceutical Industries (SUN.NS), Wockhardt (WCKH.NS), Dr Reddy’s Laboratories (REDY.NS) and Cadila Healthcare (CADI.NS) have all faced FDA rebukes over the past year.
 
Smaller firms Ipca (IPCA.NS) and Aarti Drugs (ADRG.NS) faced FDA bans on their plants this year.
 
These failures – which executives blame on India’s “quick fix” culture and consultants blame on a failure to prioritize compliance – have clouded short-term growth prospects and added to pressure on smaller players, pushing some to look elsewhere.
 
“They can choose to be in lesser-regulated markets, such as Latin America, where there is a lot of demand. But they will have to live with much thinner margins,” said the finance director of a small Indian drugmaker, who did not want to be named. “It’s survival of the fittest.”
 
By Zeba Siddiqui (Additional reporting by Sumeet Chatterjee; Editing by Clara Ferreira Marques and Muralikumar Anantharaman)

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.